Trial · NCT00000378
Antidepressant Treatment of Melancholia in Late Life
NCT00000378, Phase 4, Completed, New York State Psychiatric Institute; results first posted 2015-04-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antidepressant Treatment of Melancholia in Late Life. Trials, record NCT00000378. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00000378
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antidepressant Treatment of Melancholia in Late Life
- NCT number
- NCT00000378
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 110 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Depression, Melancholia
- Interventions
- Sertraline, Nortriptyline
- First posted
- 1999-11-03
- Last updated
- 2015-10-07
- Results first posted
- 2015-04-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HAMILTON Rating Scale for DEPRESSION Range | BASELINE COMPARED TO 12 WEEK MEASUREMENT | Hamilton scale range 0-40, values below 7 are considered normal. the higher the number the more severe the depression weekly assessments, The primary outcome is a comparison of the baseline Hamilton to the 12 week measurement |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | HAMILTON Rating Scale for DEPRESSION Range | BASELINE COMPARED TO 12 WEEK MEASUREMENT | intent to treat analysis | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| HAMILTON Rating Scale for DEPRESSION Range | Sertaline | BASELINE | 27.3 | Standard Deviation 6.6 | units on a scale |
| HAMILTON Rating Scale for DEPRESSION Range | Nortriptyline | BASELINE | 27.1 | Standard Deviation 4.4 | units on a scale |
| HAMILTON Rating Scale for DEPRESSION Range | Sertaline | 12 WEEK DATA | 10.7 | Standard Deviation 8.3 | units on a scale |
| HAMILTON Rating Scale for DEPRESSION Range | Nortriptyline | 12 WEEK DATA | 8.4 | Standard Deviation 7.7 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sertaline | 58 | |
| Overall Study | STARTED | Nortriptyline | 52 | |
| Overall Study | COMPLETED | Sertaline | 42 | |
| Overall Study | COMPLETED | Nortriptyline | 38 | |
| Overall Study | NOT COMPLETED | Sertaline | 16 | |
| Overall Study | NOT COMPLETED | Nortriptyline | 14 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | orthostatic hypotension | Cardiac disorders | Sertaline | 2 | 58 | |
| other | orthostatic hypotension | Cardiac disorders | Nortriptyline | 4 | 52 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sertaline | ||
| Total, all-cause mortality | Nortriptyline | ||
| Total, other adverse events | Sertaline | 2 | 58 |
| Total, other adverse events | Nortriptyline | 4 | 52 |
| Total, serious adverse events | Sertaline | 0 | 58 |
| Total, serious adverse events | Nortriptyline | 0 | 52 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH055716 | ANTIDEPRESSANT TREATMENT OF MELANCHOLIA IN LATE LIFE | ROOSE, STEVEN PAUL | NEW YORK STATE PSYCHIATRIC INSTITUTE | NATIONAL INSTITUTE OF MENTAL HEALTH | 1997 to 2001 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Sertaline vs Nortriptyline: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00000378
GET https://conductscience.org/api/trials/v1/NCT00000378/registered